Pacific Biosciences of California (PACB) News Today $1.13 +0.02 (+1.80%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$1.14 +0.01 (+0.88%) As of 05/2/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Sold by Oracle Investment Management Inc.Oracle Investment Management Inc. cut its holdings in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 61.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 279,638 shares of thMay 3 at 8:30 AM | marketbeat.comPacific Biosciences of California (PACB) Expected to Announce Earnings on ThursdayPacific Biosciences of California (NASDAQ:PACB) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-pacific-biosciences-of-california-inc-stock/)May 3 at 5:46 AM | marketbeat.comBarclays PLC Raises Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)Barclays PLC increased its holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 178.9% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 1,660,059 shares of the biotechnology company's stock after acquiring an additional 1,064,909May 2 at 3:43 AM | marketbeat.comSoros Fund Management LLC Increases Stock Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB)Soros Fund Management LLC lifted its holdings in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 13.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,372,265 sharesMay 1, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Makes New Investment in Pacific Biosciences of California, Inc. (NASDAQ:PACB)T. Rowe Price Investment Management Inc. purchased a new position in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 4,896,844 shares ofApril 30, 2025 | marketbeat.comPacBio Announces Plans to Improve Methylation Detection in HiFi ChemistryApril 28, 2025 | globenewswire.comCathie Wood’s ARK Investment bought 143.5K shares of PacBio todayApril 22, 2025 | markets.businessinsider.comBernstein Keeps Their Buy Rating on Pacific Biosciences (PACB)April 18, 2025 | markets.businessinsider.comVanguard Group Inc. Has $27.87 Million Stock Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)Vanguard Group Inc. lowered its stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 13.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,226,858 shares of theApril 16, 2025 | marketbeat.comPiper Sandler Sticks to Its Hold Rating for Pacific Biosciences (PACB)April 15, 2025 | markets.businessinsider.comPositive week for Pacific Biosciences of California, Inc. (NASDAQ:PACB) institutional investors who lost 57% over the past yearApril 13, 2025 | finance.yahoo.comTariffs, NIH ‘uncertainty’ force PacBio into layoffsApril 10, 2025 | bizjournals.comPacific Biosciences (PACB) Receives a Hold from BarclaysApril 10, 2025 | markets.businessinsider.comTD Cowen Remains a Buy on Pacific Biosciences (PACB)April 9, 2025 | markets.businessinsider.comPacific Biosciences of California jumps 22% after prelim Q1 results, guides FYApril 9, 2025 | seekingalpha.comSimply Good Foods, Pacific Biosciences of California, Kura Sushi, Delta Air Lines And Other Big Stocks Moving Higher On WednesdayApril 9, 2025 | benzinga.comPacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 MillionApril 9, 2025 | globenewswire.comPacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 MillionApril 9, 2025 | globenewswire.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) have received an average recommendation of "Moderate Buy" from the thirteen research firms that are covering the stock, Marketbeat reports. Six research analysts have rated the stock with a hold rating and seven haveApril 9, 2025 | marketbeat.comPacBio Grants Equity Incentive Award to New EmployeeApril 4, 2025 | globenewswire.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Short Interest Down 13.8% in MarchPacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) saw a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 53,410,000 shares, a drop of 13.8% from the February 28th total of 61,980,000 shares. Based on an average daily trading volume, of 10,840,000 shares, the days-to-cover ratio is currently 4.9 days. Currently, 20.0% of the shares of the company are sold short.April 4, 2025 | marketbeat.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Bought by Edmond DE Rothschild Holding S.A.Edmond DE Rothschild Holding S.A. lifted its stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 5.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,346,480 shares of the biotechnoloApril 1, 2025 | marketbeat.comCathie Wood’s ARK Investment bought 899K shares of PacBio todayMarch 27, 2025 | markets.businessinsider.comPacific Biosciences of California appoints CFOMarch 27, 2025 | msn.comPacific Biosciences Names Jim Gibson Chief Financial OfficerMarch 27, 2025 | marketwatch.comJim Gibson to join PacBio as Chief Financial OfficerMarch 27, 2025 | globenewswire.comScotiabank Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $2.00Scotiabank decreased their price objective on Pacific Biosciences of California from $6.00 to $2.00 and set a "sector outperform" rating for the company in a report on Tuesday.March 26, 2025 | marketbeat.comJackson Square Partners LLC Sells 1,186,850 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB)Jackson Square Partners LLC reduced its position in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 18.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,109,266 shares of the biotechnology company's sMarch 26, 2025 | marketbeat.comCathie Wood’s ARK Investment bought 415K shares of PacBio todayMarch 26, 2025 | markets.businessinsider.comAssessing Pacific Biosciences: Insights From 6 Financial AnalystsMarch 25, 2025 | benzinga.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Bought by Koss Olinger Consulting LLCKoss Olinger Consulting LLC raised its holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 150.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,000,000 sMarch 20, 2025 | marketbeat.comIs Pacific Biosciences of California, Inc. (PACB) the Most Volatile Stock Under $3 For Day Trading?March 18, 2025 | insidermonkey.comNikko Asset Management Americas Inc. Lowers Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)Nikko Asset Management Americas Inc. decreased its position in Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 14.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,178,501 shares of the biotechnology company's stock after sMarch 18, 2025 | marketbeat.comScientists Solve One of Genomics’ Biggest Challenges by Using HiFi Sequencing to Distinguish Highly Similar Paralogous GenesMarch 17, 2025 | markets.businessinsider.comScientists Solve One of Genomics' Biggest Challenges by Using HiFi Sequencing to Distinguish Highly Similar Paralogous GenesMarch 17, 2025 | globenewswire.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Sold by Bank of New York Mellon CorpBank of New York Mellon Corp lowered its position in Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 6.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,203,967 shares of the bMarch 15, 2025 | marketbeat.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of "Moderate Buy" by AnalystsShares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the thirteen brokerages that are covering the stock, MarketBeat reports. Six research analysts have rated the stock with a hold recommendation and seven havMarch 14, 2025 | marketbeat.comVestmark Advisory Solutions Inc. Acquires 276,351 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB)Vestmark Advisory Solutions Inc. increased its holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 44.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 897,058 shares of tMarch 8, 2025 | marketbeat.comBernstein Remains a Buy on Pacific Biosciences (PACB)March 4, 2025 | markets.businessinsider.comARK Investment Management LLC Boosts Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)ARK Investment Management LLC boosted its position in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 7.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 36,044,362 shares of the biotechnologFebruary 26, 2025 | marketbeat.comPacific Biosciences: Uncertain Federal Research Funding Latest Blow For Already-Battered StockFebruary 25, 2025 | seekingalpha.comPacific Biosciences of California (NASDAQ:PACB) Stock Rating Upgraded by StockNews.comStockNews.com raised shares of Pacific Biosciences of California to a "sell" rating in a research note on Tuesday.February 25, 2025 | marketbeat.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Analysts Just Slashed This Year's Revenue Estimates By 14%February 22, 2025 | finance.yahoo.comPacific Biosciences of California (NASDAQ:PACB) Given Neutral Rating at Piper SandlerPiper Sandler reaffirmed a "neutral" rating and set a $2.00 price target (down previously from $2.50) on shares of Pacific Biosciences of California in a report on Thursday.February 21, 2025 | marketbeat.comAnalysts Issue Forecasts for PACB FY2025 EarningsPacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) - Research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for shares of Pacific Biosciences of California in a research report issued to clients and investors on Tuesday, February 18th. Cantor FitFebruary 21, 2025 | marketbeat.comPacific Biosciences (PACB) Gets a Hold from Piper SandlerFebruary 20, 2025 | markets.businessinsider.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Insider Michele Farmer Sells 24,349 SharesPacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) insider Michele Farmer sold 24,349 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $1.88, for a total value of $45,776.12. Following the transaction, the insider now directly owns 187,592 shares of the company's stock, valued at $352,672.96. The trade was a 11.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.February 20, 2025 | marketbeat.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Insider Sells $45,776.12 in StockFebruary 20, 2025 | insidertrades.comTraders Purchase High Volume of Pacific Biosciences of California Call Options (NASDAQ:PACB)Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) saw some unusual options trading on Tuesday. Investors acquired 31,944 call options on the company. This is an increase of 477% compared to the typical daily volume of 5,533 call options.February 19, 2025 | marketbeat.comThe Goldman Sachs Group Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $1.50The Goldman Sachs Group lowered their price target on Pacific Biosciences of California from $1.75 to $1.50 and set a "neutral" rating for the company in a report on Tuesday.February 19, 2025 | marketbeat.com Get Pacific Biosciences of California News Delivered to You Automatically Sign up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter. Email Address PACB Media Mentions By Week PACB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PACB News Sentiment▼0.690.73▲Average Medical News Sentiment PACB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PACB Articles This Week▼64▲PACB Articles Average Week Get Pacific Biosciences of California News Delivered to You Automatically Sign up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HBIO News Today TMO News Today A News Today MTD News Today WAT News Today ILMN News Today TECH News Today BIO News Today BRKR News Today CRL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PACB) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacific Biosciences of California, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacific Biosciences of California With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PACB Stock Free PACB Stock Alerts